AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke

RecruitingNAAges 18 Years - 110 YearsAllUniversity of California, Los Angeles
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

SEACOAST 1 is a prospective, randomized, blinded endpoint trial comparing collateral vigor and clinical outcomes, with different forms of GA in patients with acute ischemic stroke due to anterior circulation large vessel occlusion (LVO) undergoing mechanical thrombectomy. The study compares GA with normocarbia (GAN) versus GA with mild hypercarbia (GAH), with a primary outcome of collateral robustness at measured at catheter angiography and clinical efficacy as secondary outcome. It is anticipated that the SEACOAST 1 will be followed by a larger, pivotal trial, SEACOAST 2, with primary clinical endpoints, in which the best method of GA identified in SEACOAST 1 is compared with the alternative strategy of anesthesia care (MAC) with minimal or no sedation. The current study focuses uppn SEACOAST 1, which is to be conducted in University of California, Los Angeles Ronald Reagan Medical Cent

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age โ‰ฅ18 2. NIHSS โ‰ฅ 6 within 0-16h or NIHSS โ‰ฅ 10 within 16-24h 3. Anterior circulation large vessel occlusion (ICA, M1, M2) 4. ASPECTS score โ‰ฅ 6 within the first 6h, or DEFUSE trial imaging criteria within 6-16h; or DAWN trial clinical/imaging mismatch criteria within 16-24h 5. Premorbid modified Rankin Scale (mRS) 0-2 6. Patient deemed candidate for mechanical thrombectomy with anticipated groin puncture within 24 hours of last known well and within 90 min of ED arrival Clinical Exclusion Criteria: 1. Intubation in ED prior to anesthesiologist evaluation, or intubation for any other medical reason other than planned thrombectomy 2. Rapid neurological improvement, suggestive of revascularization 3. Known serious sensitivity to radiographic contrast agents. 4. Current participation in another investigational drug or device treatment study. 5. Renal Failure as defined by a serum creatinine \> 2.0 mg/dl (or 176.8 ฮผmol/l) or Glomerular Filtration Rate \[GFR\] \< 30. 6. Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason. 7. Life expectancy of less than 90 days. 8. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal 9. Subject with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow up assessments. 10. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day. 11. Septic or cardiogenic shock with severe life-threatening hypotension Imaging Exclusion Criteria: 1. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of acute intracranial hemorrhage on presentation. 2. CT or MRI evidence of mass effect or intracranial tumor (except small meningioma). 3. CT showing hypodensity or MRI showing hyperintensity involving greater than 1/3 of the middle cerebral artery (MCA) territory (or in other territories, \>100 cc of tissue) on presentation. 4. Baseline non contrast CT or DWI MRI evidence of a moderate/large core defined as extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS) \< 6 5. CT or MRI evidence that ischemia is not in anterior circulation distribution. 6. Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target lesion, moderate/large infarct with poor collateral circulation, etc.). Anesthesia exclusion criteria (relative): 1. History of Malignant Hyperthermia 2. History of allergic reaction/anaphylaxis to anesthetic drugs 3. Inability to tolerate supine position (severe CHF) 4. Chronic O2 dependence or any other known pulmonary condition that might lead to difficult extubation and prolonged mechanical ventilation including known pulmonary hypertension
๐Ÿ’Š

What it tests

  • Tight control of end-tidal CO2 levels
๐Ÿ“

Where

1 site
UCLA Stroke Center
Los Angeles, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy